Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker

Journal of Hypertension, Supplement

Volumn 15, Issue 5, 1997, Pages

  Clozel, Jean Paul ^a   Ertel, Eric A ^a   Ertel, Sylvie I ^a,b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Sundgau Medical Writers ^*  (France)

Author keywords

Angina pectoris; Calcium antagonist; Hypertension; Mibefradil; Proliferation; T type calcium channel

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; VASODILATOR AGENT;

ANGINA PECTORIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY BLOOD VESSEL; DRUG SELECTIVITY; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; HYPERTENSION; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; KIDNEY; MIBEFRADIL; TETRAHYDRONAPHTHALENES; VASODILATOR AGENTS;

EID: 0031466388     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Bühler FR, Bolli P, Erne P, et al.: Position of calcium antagonists in hypertensive therapy. J Cardiovasc Pharmacol 1985, 7 (suppl 4):S21-S27.
2. Braunwald E: Calcium channel blockers: pharmacologic considerations. Am Heart J 1982, 104:665-67.
3. Opie LH: Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996, 37:273-290.
4. Vanhoutte PM: The expert commitee of the World Health Organization on classification of calcium antagonists: the viewpoint of the rapporteur. Am J Cardiol 1987, 59:3A-8A.
5. Chew CYC, Hecht HS, Collett JT, McAllister RG, Singh BN: Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 1981, 47:917-922.
6. Packer M, Kessler PD, Lee WH: Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987, 75 (suppl V):V56-V64.
7. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988, 319:385-392.
8. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989, 13:754-759.
9. Taira N: Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987, 59:24B-29B.
10. 2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries. Naunyn Schmiedebergs Arch Pharmacol 1993, 348:191-196.
11. Lacourcière Y, Poirier L, Lefebvre J, et al.: The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens 1997, 10:189-196.
12. Clozel JP, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989, 14:713-721.
13. Orito K, Satoh K, Taira N: Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol 1993, 22:293-299.
14. Hefti F, Clozel JP, Osterrieder W: Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methyl-amino]ethyl]-6-fluoro-1,2,3,4- tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil. Arzneimittelforschung 1990, 40:417-421.
15. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990, 4:731-736.
16. Karila-Cohen D, Dubois-Randé J-L, Giudicelli J-F, Berdeaux A: Effects of mibefradil on large and small coronary arteries in conscious dogs: role of vascular endothelium. J Cardiovasc Pharmacol 1996, 28:271-277.
17. Waters DD, Theroux P, Szlachcic J, Dauwe F: Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. Am J Cardiol 1981, 48:123-130.
18. Boulanger CM, Nakashima M, Olmos L, Joly G, Vanhoutte PM: Effects of the Ca antagonist RO 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol 1994, 23:869-876.
19. 2+ channel inhibitor RO 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat. Blood Press 1994, 3:193-196.
20. Veniant M, Clozel JP, Hess P, Wolfgang R: Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol 1991, 18 (suppl 10):S55-S58.
21. Bernink PJLM, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996, 27:426-432.
22. Schmitt R, Kleinbloesem CH, Belz GG, et al.: Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992, 52:314-323.
23. Ezzaher A, el Houda Bouanani N, Su JB, Hittinger L, Crozatier B: Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther 1991, 257:466-471.
24. Veniant M, Clozel JP, Hess P, Wolfgang R: Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991, 17:277-284.
25. Schmitt R, Kleinbloesem CH, Osterrieder W: Ro 40-5967 a calcium antagonist of a new generation? [abstract] Eur J Clin Pharmacol 1989, 36 (suppl):A336.
26. Portegies MC, Schmitt R, Kraaij CJ, et al.: Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991, 18:746-751.
27. Rousseau MF, Hayashida W, van Eyll C, et al.: Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996, 28:972-979.
28. Muntinga HJ, van der Vring JA, Niemeyer MG, et al.: Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 1996, 27:652-656.
29. Bonow RO, Leon MB, Rosing DR, et al.: Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in patients with coronary artery disease: radionuclide angiographic studies at rest and during exercise. Circulation 1982, 65:1337-1350.
30. Clifton D, Booth DC, Hobbs S, et al.: Negative inotropic effect of intravenous nifedipine in coronary artery disease: relation to plasma levels. Am Heart J 1990, 119:283-290.
31. Fifer MA, Aroney CN, Semigran MJ, Hermann HC, Dec GW, Boucher CA: Techniques for assessing inotropic effects of drugs in patients with heart failure: application to the evaluation of nicardipine. Am Heart J 1989, 119:451-456.
32. Stanley NN, Thirkettle JL, Varma MPS, Larkin H, Heath ID: Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension. Drugs 1988, 35:29-35.
33. Bellet M, Sassano P, Guyenne T, Corvol P, Ménard J: Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. Br J Clin Pharmacol 1987, 24:465-472.
34. Lindqvist M, Kahan T, Melcher A, Hjemdahl P: Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994, 24:287-296.
35. Su J, Renaud N, Carayon A, Crozatier B, Hittinger L: Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol 1994, 113:395-402.
36. Veniant M, Heudes D, Clozel JP, Bruneval P, Ménard J: Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 1994, 46:421-429.
37. Karam H, Heudes D, Hess P, et al.: Respective role of humoral factors and blood presure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res 1996, 31:287-295.
38. 2+ Channels. Edited by Clozel J-P, Nargeot J, Tsien RW. Chester, UK: Adis International; 1997 (in press).
39. 2+ Channels. Edited by Clozel J-P, Nargeot J, Tsien RW. Chester, UK: Adis International; 1997 (in press).
40. Wiltshire HR, Harris SR, Prior KJ, Kozlowski UM, Worth E: Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway. Xenobiotica 1992, 22:837-857.
41. Skerjanec A, Tawfik S, Tarn YK: Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs. J Pharmacol Exp Ther 1996, 278:817-825.
42. Welker HA, Eggers H, Kleinbloesern C, et al.: Ro 40-5967: pharmacokinetics of a new calcium antagonist [abstract]. Eur J Clin Pharmacol 1989, 36 (suppl):A304.
43. Follath F, Ha HR, Schuetz E, Bühler FR: Pharmacokinetics of conventional and slow-release verapamil. Br J Clin Pharmacol 1986, 21 (suppl):149S-153S.
44. Kleinbloesem CH, van Brummelen P, Faber H, Danhoff M, Vermeulen NPE, Breimer DD: Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984, 33:3721-3724.
45. Lewis JE, Balfour IDC, Brown SG, Edin AE, Walker SD: Diltiazem in hypertension: a preliminary dose-finding and efficacy multicenter study. Curr Ther Res 1985, 37:566-579.
46. 2+ channels by Ro 40-5967. Circ Res 1994, 75:144-148.
47. 2+ Channels. Edited by Clozel J-P, Nargeot J, Tsien RW. Chester, UK: Adis International;1997 (in press).
48. 2+ antagonist Ro 40-5967: consequences on heart rate and cardiac output [abstract]. Biophys J 1997, 72:A256.
49. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol 1995, 48:540-549.
50. Ertel SI, Ertel EA, Clozel J-P: T-type Ca channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther 1997 (in press).
51. Zhou Z, Lipsius SL: T-type calcium current in latent pacemaker cells isolated from cat right atrium. J Mol Cell Cardiol 1994, 26:1211-1219.
52. Hagiwara N, Irisawa H, Kameyama M: Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol Lond 1988, 395:233-253.
53. Li J, Nathan RD: Ionic basis of ryanodine's negative chronotropic effect on S-A node pacemaker cells [abstract]. Biophys J 1997, 72:A49.
54. Barrett PQ, Ertel EA, Smith MM, Nee JJ, Cohen CJ: Dual effect of calcium entry through voltage-gated Ca channels on the secretion of aldosterone [abstract]. Biophys J 1993, 64:A116.
55. Rossier MF, Python CP, Capponi AM, Schlegel W, Kwan CY, Valloton MB: Blocking T-type calcium channels with tetrandrine inhibits steroidogenesis in bovine adrenal glomerulosa cells. Endocrinology 1993, 132:1035-1043.
56. 2+ influx induced by vasoactive hormones or depletion of intracellular calcium stores. Arzneimittel Forsch Drug Res 1997, 47:244-247.
57. Rampe D, Triggle DJ: New synthetic ligands for L-type voltage-gated calcium channels. Prog Drug Res 1993, 40:191-238.
58. 2+ channel in cardiac tissue. Eur J Pharmacol 1995, 280:155-158.
59. Schuster A, Lacinová L, Klugbauer N, Ito H, Birnbaumer L, Hofmann F: The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. EMBO J 1996, 15:2365-2370.
60. 2+ channels [abstract]. Biophys J 1996, 70:A315.
61. ++ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy. Eur J Pharmacol 1991, 196:205-207.
62. ++ channels. J Pharmacol Exp Ther 1994, 271:1483-1488.
63. ++ channels by Ro 40-5967. J Pharmacol Exp Ther 1994, 269:178-183.
64. Ménard J, Karam H, Véniant M, Heudes D, Bruneval P, Clozel J-P: Effects of calcium blockade on end-organ damage in experimental hypertension. J Hypertens 1997, 15 (suppl 3):S19-S30.
65. Wenzel UO, Helmchen U, Schoeppe W, Schwietzer G: Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 1994, 23:114-122.
66. Petrie JR, Glen SK, MacMahon M, Crome R, Meredith PA, Elliott HL, Reid JL: Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. J Hypertens 1995, 13:1842-1846.
67. Guth BD: Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc Drugs Ther 1992, 6:167-171.
68. Billman GE: Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur J Pharmacol 1992, 229:179-187.
69. Richard V, Tron C, Blanc T, Thuillez C: Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil. J Cardiovasc Pharmacol 1995, 25:552-557.
70. Vander Heide RS, Schwartz LM, Reimer KA: The novel calcium antagonist Ro 40-5967 limits myocardial infarct size in the dog. Cardiovasc Res 1994, 28:1526-1532.
71. Roux S, Bühler M, Clozel JP: Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine. J Cardiovasc Pharmacol 1996, 27:132-139.
72. Janse MJ, Kléber AG: Electrophysiological changes and ventricular arrhythmias in the early phase of regional myocardial ischemia. Circ Res 1981, 49:1069-1081.
73. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group. Am Heart J 1995, 130:748-757.
74. Vacher E, Richer C, Fornes P, Clozel JP, Giudicelli JF: Mibefradil, a selective calcium T-channel blocker in stroke-prone spontaneously hypertensive rats. J Cardiovas pharmacol 1996, 27:686-694.
75. Veniant M, Gray GA, Heudes D, Menard J, Clozel JP: Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats. J Hypertens 1995, 13:731-737.
76. Gray GA, Clozel M, Clozel JP, Baumgartner HR: Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats. Hypertension 1993, 22:569-576.
77. Schmitt R, Clozel JP, Iberg N, Bühler FR: Mibefradil prevents neointima formation after vascular injury in rats: possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 1995, 15:1161-1165.
78. Schmitt R, Clozel J-P, Iberg N, Bühler FR: Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition. Cardiovasc Drugs Ther 1996, 10:101-105.
79. Fingerle J, Müller RKM, Kuhn H, Pech M, Baumgartner HR: Mechanism of inhibition of neointima formation by the angiotensin converting enzyme inhibitor cilazapril. Arterioscler Thromb Vasc Biol 1995, 15:1945-1950.
80. Nyborg NCB, MJ Mulvany: Lack of effect of antihypertensive treatment with felodipine on cardiovascular structure of young spontaneously hypertensive rats. Cardiovasc Res 1985, 19:528-536.
81. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996, 27:245-250.
82. Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991, 39:1112-1117.
83. Harris DCH, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987, 31:41-46.
84. Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G: Adverse effect of calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992, 20:233-241.
85. Jesperson CM: The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction: The Danish Group on Verapamil in Myocardial Infarction. Eur Heart J 1993, 14:540-545.
86. Cohn J, Ziesche SM, Loss LE, et al.: Effect of felodipine on short-term mortality in heart failure: results of V-HeFT III [abstract 0577]. Circulation 1995, 92 (suppl I):I143.
87. O'Connor CM, Bellum RN, Carson PE, et al.: Effect of amlodipine on the mode of death in severe chronic heart failure: the PRAISE Trial [abstract 0576]. Circulation 1995, 92 (suppl I):I143.
88. Cremers B, Flesh M, Südkamp M, Böhm M: Cardiodepressant effects of the novel calcium channel antagonist mibefradil (Ro 40-5967) in comparison with nifedipine and verapamil in human myocardium. J Cardiovasc Pharmacol 1997 29:692-696.
89. Mulder P, Richard V, Compagnon P, et al.: Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997, 29:416-421.
90. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993, 73:777-782.
91. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994, 75:149-155.
92. Xu X, Best PM: Increase in T-type calcium current in atrial myocytes from adult rats with growth hormone-secreting tumors. Proc Natl Acad Sci USA 1990, 87:4655-4659.
93. Furukawa T, Ito H, Nitta J, et al.: Endothelin-I enhances calcium entry through T-type calcium channels in cultured neonatal rat ventricular myocytes. Circ Res 1992, 71:1242-1253.
94. 2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts. Am J Physiol 1993, 265:C1239-C1246.